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Summary
Background.— Heart-fatty acid binding protein (h-FABP) has been proposed as a cardiac marker
for the early detection of acute coronary syndrome (ACS). In a study of 677 patients admitted to(ED) for chest pain, we found that a semiquantitative point-of-caresyndrome; the emergency department
Heart-fatty acid
binding protein;
Myocardial
infarction;
test that detects h-FABP (Cardiodetect®) had low sensitivity for the prediction of ACS.
Objective.— The aim of this ancillary study was to analyze and compare the performance of
h-FABP for early ACS diagnosis in this large cohort of unselected patients, using a quantitative
immunoassay and Cardiodetect®.
Abbreviations: ACS, acute coronary syndrome; AMI, acute myocardial infarction; CI, conﬁdence interval; cTnI, cardiac troponin I; ED,
mergency department; ELISA, enzyme-linked immunosorbent assay; h-FABP, heart-fatty acid binding protein; IQR, interquartile range;
STEMI, non-ST-segment elevation myocardial infarction; ROC, receiver operating characteristic; STEMI, ST-segment elevation myocardial
nfarction.
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Point-of-care testing;
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Methods.— h-FABP was measured with a ready-to-use, solid-phase, enzyme-linked immunosor-
bent assay (ELISA) in 677 patients admitted to the ED with chest pain and suspected
non-ST-segment elevation ACS. Two physicians, blinded to the results of the marker, categorized
patients as having or not having non-ST-segment elevation ACS.
Results.— Non-ST-segment elevation ACS was diagnosed in 185 patients (27.3%). The median
h-FABP level was higher in patients with ACS (1.36g/L, interquartile range [IQR] 0.59—3.55)
than in those without ACS (0.58g/L, IQR 0.24—1.34; P < 0.01). The area under the curve was
0.68 (95% conﬁdence interval [CI] 0.63—0.73). h-FABP did not improve the performance of
a model that included the usual diagnostic tools for ACS management (odds ratio 0.92, 95%
CI 0.32—2.70). The classiﬁcation agreement between the ELISA and Cardiodetect® was 92.1%
(kappa 0.39).
Conclusion.— In this study, we conﬁrmed that measurement of h-FABP was insufﬁcient to be
used as a marker of ACS and NSTEMI in ED, whatever the analytical technique used.
© 2011 Elsevier Masson SAS. All rights reserved.
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Résumé
Contexte.— L’heart-fatty acid binding protein (h-FABP) a été proposée comme marqueur car-
diaque pour la détection précoce d’un syndrome coronaire aigu (SCA). Dans une étude de 677
patients admis pour douleur thoracique dans un service d’urgence, nous avons trouvé que le test
semi-quantitatif Cardiodetect® qui mesure l’h-FABP avait une faible sensibilité pour prédire le
diagnostic de SCA.
Objectifs.— L’objectif de cette étude ancillaire est d’analyser et de comparer les performances
de l’h-FABP mesurées par une méthode immunologique quantitative à celles mesurées avec
le Cardiodetect® mesurée par une méthode semi-quantitative pour le diagnostic de SCA sans
élévation du segment ST dans une large cohorte de patients non sélectionnés.
Méthodes.— L’h-FABP a été mesurée par un dosage immuno-enzymatique sur support solide
(Elisa) chez 677 patients admis aux urgences pour une douleur thoracique évocatrice de SCA
sans élévation du segment ST. Deux médecins en aveugle des résultats des dosages ont catégorisé
les patients en deux groupes avec ou sans SCA.
Résultats.— Le diagnostic de SCA était fait chez 185 patients (27,3 %). La valeur médiane de
l’h-FABP des patients avec SCA (1,36g/L, interquartile range [IQR] 0,59—3,55) était supérieure
à celle des patients sans SCA (0,58g/L, IQR 0,24—1,34 ; p < 0,01). L’aire sous la courbe était
0,68 (intervalle de conﬁance [IC] 95 % 0,63—0,73). L’h-FABP n’améliorait pas les performances
du modèle incluant les outils habituellement utilisés pour le diagnostic de SCA (odds ratio 0,92,
IC 95% 0,32—2,70). La concordance entre le test Elisa et le Cardiodetect® était de 92,1 % (kappa
0,39).
Conclusion.— Cette étude conﬁrme que les performances de l’h-FABP sont insufﬁsantes pour
utiliser ce test comme marqueur de SCA aux urgences, quelle que soit la méthode de dosage
utilisée.
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Background
The diagnosis of acute coronary syndrome (ACS) in uns-
elected chest pain patients presenting to the emergency
department (ED) remains challenging for physicians [1,2].
Besides the new highly sensitive troponin assays, very early
biomarkers of cardiac damage, such heart-fatty acid bind-
ing protein (h-FABP), may prove to be diagnostically superior
[3,4]. Point-of-care tests have been developed to make an
early ACS diagnosis [5]. We recently reported that the semi-
quantitative assay of h-FABP (Cardiodetect®) predicted ACS
diagnosis with high speciﬁcity (96.8%) but low sensitivity
(13.5%) in a prospective study of 677 consecutive patients
admitted to our ED for chest pain [6]. This test did not
provide signiﬁcant incremental information to a predictive
model that included the usual tools for non-ST-segment
elevation ACS management. A better h-FABP performance
S
T
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or ACS diagnosis was found with a quantitative assay in a
elected population for ACS risk [4]. We hypothesize that
he low performance of h-FABP found in our population was
elated to the semiquantitative assay used.
The aim of this study was, therefore, to analyze and com-
are the performance of h-FABP for early ACS diagnosis in
his large cohort of unselected patients, using a quantita-
ive immunoassay and the semiquantitative Cardiodetect®
ssay.
ethods
tudy designhis was an ancillary study of a large, prospective, single-
entre study of diagnostic accuracy, published recently [6].
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at 7 ng/mL, the performances of h-FABP for ACS and NSTEMI
diagnoses were reported (Table 2). The h-FABP sensitivities
were 15.7% (95% CI 12.9—18.4) and 26.3% (95% CI 22.9—29.6)26
his second analysis was done retrospectively. The institu-
ional review board approved the study protocol.
tudy setting and population
he study was carried out at a large urban university hospital
s previously described [6]. Brieﬂy, 677 patients admitted
o the ED with chest pain evolving within 12 hours and
uspected of having ACS were included by the emergency
reating physician. Patients with ST-segment elevation on
12-lead electrocardiogram were excluded. Patients signed
nformed written consent before inclusion in the main study,
or the main study, for the serum bank and for analysis of
he sample from the serum bank to study new biomarkers in
he context of ACS.
tudy protocol
fter obtaining written consent, the clinical history, physi-
al evaluation, serial 12-lead electrocardiogram, standard
lood tests, cardiac troponin I (cTnI) measurements and
hest X-rays were performed for all patients according to
he usual procedures and reported on a case report form by
he treating physician. After 1 month, major cardiac events,
ncluding death, admission to hospital for ACS and the results
f the cardiovascular diagnostic tests carried out during the
0 days after ED discharge, were collected by the research
ssistant. The diagnosis of ACS, based on current interna-
ional guidelines, was made by two independent experts as
reviously described [6]. Patients with ACS were classiﬁed
s having non-ST-segment elevation myocardial infarction
NSTEMI) when the cTnI was above 0.1g/L on serial testing.
tudy measurements
erial plasma samples were collected shortly after ED
dmission, and were immediately centrifuged. cTnI concen-
rations were measured immediately on an Advia Centaur
nIc system (Bayer Diagnostics, Leverkusen, Germany) (99th
ercentile at 0.1g/L) at admission and after 6 hours.
Plasma samples at admission were frozen at —80 ◦C and
he h-FABP assays were performed a few months later.
he h-FABP enzyme-linked immunosorbent assay (ELISA) test
as based on the principle of a ready-to-use, solid-phase
LISA (HyCult Biotech, Uden, The Netherlands). The acute
yocardial infarction (AMI) cut-off concentrations reported
n other studies were between 5 and 7.3 ng/mL [7—9]. Mea-
urement of the h-FABP ELISA test was performed by the
iologist, who was blinded to the Cardiodetect® results and
o the ﬁnal diagnosis. Data analysis of the performance of
he quantitative h-FABP was performed blinded to the per-
ormance of Cardiodetect®.
ata analysis
aseline characteristics were assessed using Student’s t test
r the Mann-Whitney U test for continuous variables and the
hi2 test for categorical variables. P values less than 0.05
ere taken as signiﬁcant. Receiver operating characteris-
ic (ROC) curves were used to evaluate the performance of
he ELISA h-FABP assay for the ﬁnal diagnosis of ACS and
STEMI. The cut-off level of 7 ng/mL was used to assess
F
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linical sensitivity and speciﬁcity. Classiﬁcation agreement
f the two tests (ELISA h-FABP and Cardiodetect®) for the
ut-off value of 7 ng/mL was examined using the kappa test.
To assess if plasma h-FABP levels provided additional
nformation beyond the criteria usually used for ACS diag-
osis, we compared the model with the usual immediately
vailable data for the diagnosis of ACS as described pre-
iously and a model with the h-FABP values in addition
o the previous variables. The usual available data were:
ge, sex, cardiovascular risk factors (smoking status, hyper-
ipidaemia, diabetes, family history of ischaemic heart
isease, hypertension), previous coronary artery syndrome,
linical presentation with persistent chest pain, ischaemic
lectrocardiogram abnormalities and cTnI measurement on
dmission. A likelihood ratio test was carried out between
oth models and the accuracy of each was calculated for a
ut-off at 0.5.
esults
mong 677 consecutive patients (454 men, 223 women,
ean age 57± 17 years) included in the study, non-ST-
egment elevation ACS was diagnosed in 185 patients (27.3%)
ncluding 99 NSTEMIs (53.5%). The classiﬁcation agreement
etween the experts for ACS status measured by the kappa
est was 0.71. Baseline characteristics of the patients are
eported Table 1.
The median h-FABP level was signiﬁcantly higher in
atients with ACS (1.36g/L, interquartile range [IQR]
.59—3.55) and with NSTEMI (2.25g/L, IQR 0.74—7.36)
han in patients with a diagnosis of non-ischaemic chest pain
0.58g/L, IQR 0.24—1.34; P < 0.01).
The area under the curve was 0.68 (95% conﬁdence inter-
al [CI] 0.63—0.73) and 0.74 (95% CI 0.69—0.80) for ACS and
STEMI diagnosis, respectively (Fig. 1). For the cut-off leveligure 1. Receiver operating characteristic (ROC) curves of
eart-fatty acid binding protein (h-FABP) for acute coronary syn-
rome diagnosis.
I: conﬁdence interval.
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Table 1 Baseline characteristics of the patient group based on the diagnosis of non-ST-segment elevation acute coronary
syndrome.
Variable Acute coronary syndrome Non-ischaemic chest pain P
Patients 185 (27.3) 492 (72.7)
Age (years) 67.3± 15.3 53.7± 15.5 < 0.001
Men 125 (67.6) 329 (66.9) 0.86
Risk factors
Diabetes 39 (21.1) 46 (9.4) < 0.001
Hyperlipidaemia 106 (57.3) 163 (33.2) < 0.001
Smokers 36 (19.6) 160 (32.7) < 0.01
Ex-smokers 71 (38.6) 132 (27.0) < 0.01
Hypertension 121 (65.8) 164 (33.4) < 0.001
Family history of CAD 63 (34.2) 147 (30.1) 0.29
Previous CAD 103 (55.7) 103 (20.9) < 0.001
Body mass index (kg/m2) 26.3± 4.6 26.0± 4.9 0.48
Delay from chest pain to management (minutes)
Time to inclusion 150 (90—230) 132 (84—240) 0.61
Time to blood taking 176 (104—260) 170 (104—270) 0.89
Total duration of chest pain (minutes) 90 (45—180) 79.5 (30—180) 0.43
Admission presentation
Persistent chest pain 79 (47.3) 207 (47.5) 0.97
ECG abnormalities 64 (34.6) 47 (9.6) < 0.001
Elevated troponin 55 (28.9) 8 (1.63) < 0.001
Markers
Quantitative h-FABP (g/L) 1.36 (0.59—3.55) 0.58 (0.24—1.34) < 0.01
Elevated quantitative h-FABP (cut-off 7g/L) 29 (15.7) 14 (2.9) < 0.001
Elevated h-FABP (Cardiodetect®) 25 (13.5) 16 (3.25) < 0.001
Data are mean± standard deviation, median (interquartile range) or number (%). The body mass index is the weight in kg divided by
the square of the height in metres. ACS: acute coronary syndrome; CAD: coronary artery disease; ECG: electrocardiogram; h-FABP:
heart-fatty acid binding protein.
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Cand the speciﬁcities were 97.2% (95% CI 95.9—98.4) and
97.1% (95% CI 95.8—98.3) for the ACS and NSTEMI diagnoses,
respectively.
The initial cTnI sensitivity and speciﬁcity for NSTEMI diag-
nosis were 56.1% (95% CI 52.4—59.9) and 98.6% (95% CI
97.7—99.5), respectively.
When added to the model that used the usual immedi-
ately available data in the ED for ACS or NSTEMI diagnosis,
a
p
w
Table 2 Performances of heart-fatty acid binding protein for d
elevation myocardial infarction for a cut-off level at 7 ng/mL.
ACS
Sensitivity 15.7 (1
Speciﬁcity 97.2 (9
Positive likelihood ratio 5.5
Negative likelihood ratio 0.87
Positive predictive value 67.4 (6
Negative predictive value 75.4 (7
Data are % (95% conﬁdence interval), unless otherwise indicated. AC
myocardial infarction.-FABP did not signiﬁcantly improve the performance of this
odel (odds ratio 0.92, 95% CI 0.32—2.70 for ACS; odds ratio
.89, 95% CI 0.22—3.63 for NSTEMI).
The concordance of the results obtained with
ardiodetect® and the h-FABP quantitative assay using
cut-off level of 7 ng/mL was studied. We found that 611
atients (90.2%) were negative with both assays, 18 (2.7%)
ere positive with both assays and 48 (7.1%) were positive
iagnosis of acute coronary syndrome and non-ST-segment
NSTEMI
2.9—18.4) 26.3 (22.9—29.6)
5.9—98.4) 97.1 (95.8—98.3)
8.9
0.76
3.9—71.0) 60.5 (56.8—64.2)
2.2—78.6) 88.5 (86.1—90.9)
S: acute coronary syndrome; NSTEMI: non-ST-segment elevation
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nly with either the semiquantitative or the quantitative
ssay. The global classiﬁcation agreement was 92.1% and
he kappa coefﬁcient was low (0.39).
iscussion
he result of this study demonstrated that quantitative mea-
urement of h-FABP did not perform any better than the
emiquantitative Cardiodetect® assay. These results led us
o believe that h-FABP, whatever the analytical technique
sed, has no incremental value for the early detection of
CS in a non-selected population of patients with ACS,
xcept ST-segment elevation myocardial infarction (STEMI).
his conclusion seems inconsistent with other authors who
eported higher h-FABP sensitivity for AMI diagnosis [3,4].
owever, these latter studies included patients with STEMI
nd excluded troponin-negative patients with ACS [5,8—10].
n a recent publication, h-FABP sensitivity was measured at
4% for patients with chest pain within 3 hours of symptom
nset but half of the AMI patients had STEMI [10]. In our
tudy, only 14.6% of NSTEMI were diagnosed. Our patients
ad less myocardial damage and it is known that minor
yocardial damage releases low amounts of h-FABP into the
irculation and the sensitivity of the test is decreased in
hese situations [11,12]. Glatz et al. showed that h-FABP
as a marker for the estimation of the size of a myocar-
ial infarct in patients with STEMI diagnosis [12]. In a recent
tudy, Haltern et al. conﬁrmed that the discriminative value
f h-FABP was poor in patients with NSTEMI and that the ROC
urve was close to the diagonal [7].
Another explanation of the difference compared with
ther studies is the role of the reference standard used in
revious studies. In a recent systematic review and meta-
nalysis of 16 studies, the overall sensitivity and speciﬁcity
f h-FABP for AMI diagnosis were 84% (95% CI 76—90) and
4% (95% CI 76—89), respectively [13]. The authors reported
n a covariate analysis that the use of troponin instead of
reatine kinase as a reference standard for AMI had a sig-
iﬁcant impact on sensitivity. The sensitivity of h-FABP in
tudies using troponin (0.76 95% CI 0.67—0.84) was signif-
cantly lower than in those that did not use troponin as a
eference standard (0.91 95% CI 0.84—0.95). The authors
oncluded that h-FABP used alone does not allow safe and
arly diagnosis of AMI. The use of a more highly sensitive
roponin assay should further decrease the accuracy of h-
ABP. A recent study showed that the area under the curve
f sensitive troponin I (0.91) was higher than that of h-FABP
0.86) in the early hours of ACS [14].
Beyond the poor performance of h-FABP, we conﬁrmed
hat h-FABP did not provide incremental information in addi-
ion to the clinical features used for ACS diagnosis in an
D.
tudy limitationshe major limitations were reported in the previous article
6]. The classiﬁcation agreement between the experts was
ot perfect because a diagnosis of unstable angina is difﬁcult
o make in an ED. However, the performance of h-FABP for
he diagnosis of NSTEMI diagnosis was also poor.S. Charpentier et al.
onclusion
n this study, we conﬁrmed that the performance of h-FABP
ssays was insufﬁcient for it to be used as a marker for
he diagnosis of ACS and NSTEMI in an ED, whatever the
nalytical technique used. h-FABP did not provide useful
nformation for ACS diagnosis in patients admitted to an ED
ith chest pain.
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